AR129362A1 - Oligonucleótidos mejorados que actúan sobre sitios de proteína de unión de arn - Google Patents
Oligonucleótidos mejorados que actúan sobre sitios de proteína de unión de arnInfo
- Publication number
- AR129362A1 AR129362A1 ARP230101237A ARP230101237A AR129362A1 AR 129362 A1 AR129362 A1 AR 129362A1 AR P230101237 A ARP230101237 A AR P230101237A AR P230101237 A ARP230101237 A AR P230101237A AR 129362 A1 AR129362 A1 AR 129362A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- binding protein
- rna binding
- act
- antisense oligonucleotide
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 4
- 101710159080 Aconitate hydratase A Proteins 0.000 title abstract 2
- 101710159078 Aconitate hydratase B Proteins 0.000 title abstract 2
- 102000044126 RNA-Binding Proteins Human genes 0.000 title abstract 2
- 101710105008 RNA-binding protein Proteins 0.000 title abstract 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 6
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 6
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 3
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 abstract 2
- 101710150875 TAR DNA-binding protein 43 Proteins 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 108020004999 messenger RNA Proteins 0.000 abstract 2
- YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000027455 binding Effects 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 125000003835 nucleoside group Chemical group 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004853 protein function Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22174186 | 2022-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129362A1 true AR129362A1 (es) | 2024-08-14 |
Family
ID=82308571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230101237A AR129362A1 (es) | 2022-05-18 | 2023-05-18 | Oligonucleótidos mejorados que actúan sobre sitios de proteína de unión de arn |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250290068A2 (OSRAM) |
| EP (1) | EP4526445A1 (OSRAM) |
| JP (1) | JP2025518522A (OSRAM) |
| KR (1) | KR20250011958A (OSRAM) |
| CN (1) | CN119213124A (OSRAM) |
| AR (1) | AR129362A1 (OSRAM) |
| AU (1) | AU2023270744A1 (OSRAM) |
| CA (1) | CA3257367A1 (OSRAM) |
| CL (1) | CL2024003521A1 (OSRAM) |
| CO (1) | CO2024017326A2 (OSRAM) |
| CR (1) | CR20240492A (OSRAM) |
| IL (1) | IL316608A (OSRAM) |
| MX (1) | MX2024014159A (OSRAM) |
| PE (1) | PE20250394A1 (OSRAM) |
| TW (1) | TW202409276A (OSRAM) |
| WO (1) | WO2023222858A1 (OSRAM) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7836475B1 (ja) | 2024-03-05 | 2026-03-26 | 武田薬品工業株式会社 | Ｕｎｃ１３ａのスプライシングモジュレーションのための組成物および方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| CA2303299C (en) | 1997-09-12 | 2016-02-23 | Exiqon A/S | Oligonucleotide analogues |
| PT1152009E (pt) | 1999-02-12 | 2005-03-31 | Sankyo Co | Novos analogos de nucleosidos e oligonucleotidos |
| NZ514348A (en) | 1999-05-04 | 2004-05-28 | Exiqon As | L-ribo-LNA analogues |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| US9045518B2 (en) | 2002-11-18 | 2015-06-02 | Santaris Pharma A/S | Amino-LNA, thio-LNA and alpha-L-oxy-LN |
| ES2351674T3 (es) | 2006-01-27 | 2011-02-09 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos modificados en la posición 6. |
| US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| EP2170917B1 (en) | 2007-05-30 | 2012-06-27 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| EP2176280B2 (en) | 2007-07-05 | 2015-06-24 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
| US8501805B2 (en) | 2008-09-24 | 2013-08-06 | Isis Pharmaceuticals, Inc. | Substituted alpha-L-bicyclic nucleosides |
| US9012421B2 (en) | 2009-08-06 | 2015-04-21 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| WO2011156202A1 (en) | 2010-06-08 | 2011-12-15 | Isis Pharmaceuticals, Inc. | Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| EP2850092B1 (en) | 2012-04-09 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
| SG10201804331TA (en) | 2012-11-15 | 2018-07-30 | Roche Innovation Ct Copenhagen As | Oligonucleotide conjugates |
| JP2017505623A (ja) | 2014-01-30 | 2017-02-23 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 生物切断性コンジュゲートを有するポリオリゴマー化合物 |
| US11833168B2 (en) | 2018-06-14 | 2023-12-05 | Ionis Pharmaceuticals, Inc. | Compounds and methods for increasing STMN2 expression |
| MX2021005357A (es) * | 2018-11-08 | 2021-06-30 | Aligos Therapeutics Inc | Polimeros oligonucleotidos que inhiben el transporte de antigeno s y metodos. |
| WO2022018187A1 (en) * | 2020-07-23 | 2022-01-27 | F. Hoffmann-La Roche Ag | Oligonucleotides targeting rna binding protein sites |
| CN118434858A (zh) * | 2021-12-07 | 2024-08-02 | 豪夫迈·罗氏有限公司 | 靶向actl6b的反义寡核苷酸 |
-
2023
- 2023-05-18 KR KR1020247041783A patent/KR20250011958A/ko active Pending
- 2023-05-18 IL IL316608A patent/IL316608A/en unknown
- 2023-05-18 CR CR20240492A patent/CR20240492A/es unknown
- 2023-05-18 PE PE2024002546A patent/PE20250394A1/es unknown
- 2023-05-18 AR ARP230101237A patent/AR129362A1/es unknown
- 2023-05-18 TW TW112118586A patent/TW202409276A/zh unknown
- 2023-05-18 JP JP2024568256A patent/JP2025518522A/ja active Pending
- 2023-05-18 CN CN202380040019.6A patent/CN119213124A/zh active Pending
- 2023-05-18 AU AU2023270744A patent/AU2023270744A1/en active Pending
- 2023-05-18 WO PCT/EP2023/063442 patent/WO2023222858A1/en not_active Ceased
- 2023-05-18 EP EP23723219.4A patent/EP4526445A1/en active Pending
- 2023-05-18 CA CA3257367A patent/CA3257367A1/en active Pending
-
2024
- 2024-11-15 MX MX2024014159A patent/MX2024014159A/es unknown
- 2024-11-15 US US18/948,897 patent/US20250290068A2/en active Pending
- 2024-11-18 CL CL2024003521A patent/CL2024003521A1/es unknown
- 2024-12-17 CO CONC2024/0017326A patent/CO2024017326A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3257367A1 (en) | 2023-11-23 |
| CO2024017326A2 (es) | 2025-03-27 |
| CL2024003521A1 (es) | 2025-03-21 |
| WO2023222858A1 (en) | 2023-11-23 |
| MX2024014159A (es) | 2024-12-06 |
| US20250290068A2 (en) | 2025-09-18 |
| EP4526445A1 (en) | 2025-03-26 |
| CR20240492A (es) | 2025-01-06 |
| PE20250394A1 (es) | 2025-02-11 |
| IL316608A (en) | 2024-12-01 |
| KR20250011958A (ko) | 2025-01-22 |
| US20250145996A1 (en) | 2025-05-08 |
| TW202409276A (zh) | 2024-03-01 |
| AU2023270744A1 (en) | 2024-11-07 |
| JP2025518522A (ja) | 2025-06-17 |
| CN119213124A (zh) | 2024-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11001841B2 (en) | CCCTC-binding factor (CTCF) RNA interactome | |
| AR108038A1 (es) | Oligonucleótidos para reducir la expresión de pd-l1 (ligando de muerte programada-1) | |
| AR123043A1 (es) | Oligonucleótidos dirigidos a sitios protéicos de unión a arn | |
| ES2689696T3 (es) | Liposomas de retinoide para potenciar la modulación de la expresión de hsp47 | |
| RU2015119409A (ru) | Конъюгаты олигонуклеотидов | |
| JP2021533804A5 (OSRAM) | ||
| CY1121894T1 (el) | Θεραπεια hbv | |
| JP2017079776A5 (OSRAM) | ||
| PE20212131A1 (es) | Compuestos y metodos para reducir de la expresion de atxn3 | |
| AR126207A1 (es) | Compuestos de oligonucleotidos anti-flt1 optimizados para el tratamiento de la preeclampsia y otros desordenes angiogénicos | |
| RU2014125496A (ru) | Комбинированная терапия для лечения нарушений слуха и равновесия | |
| JP2009524696A5 (OSRAM) | ||
| RU2016122168A (ru) | Антисмысловые конъюгаты, направленные на аполипопротеин b | |
| JP2019503394A5 (OSRAM) | ||
| JP2015502134A5 (OSRAM) | ||
| US20150218205A1 (en) | Method of preparing oligomeric compounds using modified capping protocols | |
| AR069821A1 (es) | Composiciones y metodos de uso de la interferencia de arn para el control de nematodos | |
| PE20191047A1 (es) | Compuestos y metodos para reducir de la expresion de atxn3 | |
| JP2021505129A5 (OSRAM) | ||
| RU2014121304A (ru) | Ингибирование экспрессии вирусных генов | |
| Carrette et al. | A mildly inducible and selective cross-link methodology for RNA duplexes | |
| JP2017528441A5 (OSRAM) | ||
| FI3717646T3 (fi) | Angelmanin oireyhtymän antisense-hoito | |
| WO2006032041A3 (en) | Compositions and methods for inhibiting expression of anti-apoptotic genes | |
| CO2024017326A2 (es) | Oligonucleótidos mejorados que actúan sobre sitios de proteína de unión a arn |